Zim Laboratories Ltd. (ZIMLAB) AI Stock Analysis

• Market Cap: ₹3.12B
• Dividend Yield: N/A
• Average Volume (3M): 6.28K
• Price to Earnings (P/E): 20.0
• Beta (1Y): 1.08
• Revenue Growth: -5.82%
• EPS Growth: -59.22%
• Country: IN
• Employees: 556
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.90
• Shares Outstanding: 48,735,813
• 10 Day Avg. Volume: 5,950
• 30 Day Avg. Volume: 6,279
• PEG Ratio: -1.14
• Price to Book (P/B): 1.62
• Price to Sales (P/S): 1.09
• P/FCF Ratio: 1.15K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ₹68.00 ▼(-4.37% Downside)
• Action: Reiterated Date: 10/31/25
• Date: Action: Reiterated 10/31/25

Zim Laboratories Ltd. scores moderately due to strong financial performance with revenue growth and operational efficiency. However, the stock's overvaluation and neutral technical indicators weigh down the overall score. The lack of earnings call and corporate events data limits further insights.

Positive Factors

Revenue & Operational Efficiency

Sustained revenue growth alongside improved gross and stable EBIT/EBITDA margins indicates the company can scale sales without proportionate cost increases. Over the next 2-6 months this supports durable earnings capacity and operational leverage, aiding long‑term cash generation and reinvestment.

Negative Factors

Profitability Pressure

A falling net profit margin despite revenue expansion suggests rising non-operating costs, tax, or interest burdens that erode returns. Persisting margin compression would weaken sustainable earnings power, reduce retained earnings for reinvestment, and impair long‑term shareholder value creation.

Zim Laboratories Ltd. Business Overview & Revenue Model

Company Description

ZIM Laboratories Limited develops, manufactures, and supplies pharmaceutical formulation and pre formulation ingredients in India and internationally. The company provides technology-based drug delivery solutions and non-infringing proprietary man...

Read more

ZIM Laboratories Limited develops, manufactures, and supplies pharmaceutical formulation and pre formulation ingredients in India and internationally. The company provides technology-based drug delivery solutions and non-infringing proprietary man...

How the Company Makes Money

Zim Laboratories generates revenue primarily by selling pharmaceutical formulation products. Key revenue streams include: (1) Domestic sales: revenue from marketing and distributing its branded or branded-generic formulations in India through its ...

Read more

Zim Laboratories generates revenue primarily by selling pharmaceutical formulation products. Key revenue streams include: (1) Domestic sales: revenue from marketing and distributing its branded or branded-generic formulations in India through its ...

Zim Laboratories Ltd. Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	3.66B	3.74B	3.68B	3.99B	3.31B	3.07B
Gross Profit	1.85B	730.04M	1.86B	903.81M	1.67B	1.48B
EBITDA	431.55M	495.11M	454.76M	582.00M	452.62M	355.31M
Net Income	65.86M	121.65M	172.46M	244.34M	145.50M	73.17M
Balance Sheet
Total Assets	4.70B	4.72B	4.47B	3.42B	3.42B	3.25B
Cash, Cash Equivalents and Short-Term Investments	50.12M	20.37M	96.41M	64.66M	34.20M	13.93M
Total Debt	1.23B	1.18B	1.12B	620.00M	533.14M	823.20M
Total Liabilities	2.19B	2.20B	2.08B	1.41B	1.66B	1.64B
Stockholders Equity	2.51B	2.52B	2.39B	2.00B	1.76B	1.61B
Cash Flow
Free Cash Flow	40.45M	3.57M	-576.45M	15.00M	339.81M	253.74M
Operating Cash Flow	199.18M	411.55M	162.78M	381.68M	492.06M	318.51M
Investing Cash Flow	-155.70M	-399.27M	-730.13M	-362.04M	-145.71M	-58.81M
Financing Cash Flow	-34.19M	-91.05M	595.34M	5.46M	-329.70M	-259.74M

Zim Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 71.11
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZIMLAB, the sentiment is Negative. The current price of 71.11 is above the 20-day moving average (MA) of 66.80, above the 50-day MA of 70.52, and below the 200-day MA of 80.08, indicating a bearish trend. The MACD of -1.71 indicates Positive momentum. The RSI at 41.90 is Neutral, neither overbought nor oversold. The STOCH value of 28.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ZIMLAB.

Zim Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	79 Outperform	₹11.62B	10.01	―	―	13.32%	218.38%
ZIMLAB	63 Neutral	₹3.12B	19.99	―	―	-5.82%	-59.22%
MEDICAMEQ	55 Neutral	₹3.23B	56.53	―	0.26%	-9.16%	49.09%
LYKALABS	54 Neutral	₹1.66B	-338,564.26	―	―	4.04%	-35.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALBERTDAVD	51 Neutral	₹3.47B	6.87	―	0.66%	-13.51%	-122.00%
NECLIFE	48 Neutral	₹2.20B	7.63	―	―	-30.27%	-3470.06%

Zim Laboratories Ltd. Corporate Events